Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 1997

View Archived Issues

Clinical results in NIDDM reported for troglitazone

Pioglitazone improves insulin resistance in NIDDM

New preclinical studies on JTT-501

Phase III results for AY-4166

Clinical safety and efficacy of TS-110 for inflammation and pain

Carbovir not associated with mitochondrial toxicity in intact cells

BRL-48482 has potential for reducing cardiovascular risk in NIDDM

Paracelsian cancels launch of AndroVir

Novel site of action for chimeric insulin-releasing peptide

Otsuka AGE inhibitor prevents progression of diabetic nephropathy in animal model

Novopharm Biotech files Canadian IND for hMAb

Promising preliminary results with Oncor's HER-2/neu in prostate trial

M-16049: hypoglycemic agent and aldose reductase inhibitor

Mylan files ANDA for generic nifedipine

MedImmune: Q1 1997 highlights

Cambridge Antibody Technology: Six-month results and highlights

Ergoset clinical study results presented at diabetes congress

A wealth of clinical data on pramlintide presented at diabetes congress

FDA clears Hemagen Diagnostics' test for connective tissue diseases

Arris and Abbott sign licensing agreement

Harvard Medical School and Hoechst Marion Roussel enter research agreement

Alfa Wassermann and Merckle sign development and marketing agreement for rifaximin

Paracelsian cancels launch of AndroCar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...